Inhibrx Biosciences’ INBRX-106 combination produced a 48.3% confirmed response rate in Phase 2 HNSCC, versus 26.5% for pembrolizumab alone. The results support expansion of the randomized study, planned FDA alignment and a Phase 3 confirmatory trial, while additional 2027 lung-cancer data could broaden development.

Key Highlights

  • HPV-positive patients recorded an 80.0% confirmed response rate with the combination versus 33.3% for pembrolizumab monotherapy.
  • Inhibrx plans to expand the HexAgon Phase 2 study and pursue a Phase 3 confirmatory trial.
  • Median progression-free survival was 9.6 months with the combination versus 4.9 months with pembrolizumab alone.

Inhibrx Biosciences, Inc. (NASDAQ: INBX) reported a 48.3% confirmed objective response rate for INBRX-106 plus pembrolizumab in a randomized Phase 2 HNSCC study. Pembrolizumab alone produced a 26.5% response rate, giving the combination the higher result in the primary endpoint analysis.

HexAgon Data Show Longer Progression-Free Survival

The analysis used data cut off on August 19, 2026, and showed median progression-free survival of 9.6 months for the combination versus 4.9 months for pembrolizumab alone. Six-month progression-free survival rates were 72.4% and 42.8%, respectively. Four patients, or 13.8% of those receiving the combination, achieved a complete response, compared with none in the control arm. Among patients with HPV-positive disease, confirmed response rates were 80.0% with the combination and 33.3% with pembrolizumab alone, while six-month progression-free survival was 90.0% versus 33.0%.

Inhibrx Plans Expansion and Phase 3 Testing

The company is also evaluating INBRX-106 in perioperative non-small cell lung cancer, with initial results targeted for 2027. Inhibrx plans to explore combinations with therapeutic cancer vaccines.